Genmab A/S (NASDAQ:GMAB) Releases Quarterly Earnings Results, Beats Estimates By $0.29 EPS

Genmab A/S (NASDAQ:GMAB) released its quarterly earnings results on Wednesday. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.29, Zacks reports. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. Genmab A/S updated its FY 2025 guidance to EPS.

Genmab A/S Stock Up 2.9 %

GMAB stock traded up $0.55 during trading on Wednesday, hitting $19.44. 1,235,404 shares of the company’s stock traded hands, compared to its average volume of 1,524,819. The firm has a market capitalization of $12.86 billion, a P/E ratio of 18.87, a PEG ratio of 0.54 and a beta of 0.96. Genmab A/S has a 1 year low of $18.64 and a 1 year high of $31.88. The business has a fifty day simple moving average of $20.72 and a two-hundred day simple moving average of $23.24.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a research report on Thursday, January 23rd. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $48.00 price objective (up from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $45.20.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.